A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT05337137
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
- Carcinoma, Hepatocellular
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Relatlimab — DRUGSpecified dose on specified days
- Nivolumab — DRUGSpecified dose on specified days
- Bevacizumab — DRUGSpecified dose on specified days
- Placebo — OTHERSpecified dose on specified days
Study Details
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
Key Dates
- Start date
- May 5, 2022
- Status verified
- Jan 2026
- Primary completion
- Jul 5, 2025
- Completion
- Nov 18, 2025
Study Design
- Enrollment
- 83 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: Relatlimab + Nivolumab + Bevacizumab
- Experimental: Arm B: Placebo + Nivolumab + Bevacizumab
Primary Outcome Measure
Incidence of dose-limiting toxicities (DLTs) [ Time Frame: Up to 6 weeks ]
Locations (10)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Local Institution - 0039 | Los Angeles | California | 90095 | - |
| Local Institution - 0042 | Los Angeles | California | 90033 | - |
| Local Institution - 0034 | San Francisco | California | 94115 | - |
| Local Institution - 0030 | Washington D.C. | District of Columbia | 20007 | - |
| Local Institution - 0059 | Baltimore | Maryland | 21231 | - |
| Local Institution - 0060 | Boston | Massachusetts | 02114 | - |
| Local Institution - 0065 | Boston | Massachusetts | 02215 | - |
| Local Institution - 0061 | New York | New York | 10065 | - |
| Local Institution - 0062 | The Bronx | New York | 10461 | - |
| Local Institution - 0033 | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Los Angeles, CA
Related Studies
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver CancerPHASE4 · Enrolling By Invitation · Baylor Research Institute · San Francisco, California
- ABX196 in Combination With Nivolumab in Patients With Hepatocellular CarcinomaPHASE1/PHASE2 · Recruiting · Abivax S.A. · La Jolla, California
- Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular CarcinomaPHASE2 · Recruiting · Rutgers, The State University of New Jersey · New Brunswick, New Jersey
- Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRIRecruiting · VA Office of Research and Development · Birmingham, Alabama